Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Park

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Acta Biomaterialia|September 6, 2017
Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticlesChristina L Parker, Qi Yang, Bing Yang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 2, 2017
Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigensQi Yang, Christina L Parker, Yukang Lin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 27, 2020
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagiaKristyn Y DiSogra, Thuy Tran, Justin R Arnall, et al.
Cancer|December 15, 2018
Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypesLaura L Hester, Steven I Park, William A Wood, et al.
Archives of Pathology & Laboratory Medicine|February 2, 2013
Diagnostic complexities of eosinophiliaNathan D Montgomery, Cherie H Dunphy, Micah Mooberry, et al.
ACS Nano|January 24, 2018
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin LymphomaKin Man Au, Ashutosh Tripathy, Carolina Pe-I Lin, et al.
The Lancet. Oncology|November 19, 2013
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation studyAnas Younes, Joseph M Connors, Steven I Park, et al.
Blood Advances|June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Cancer Research Communications|March 6, 2023
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell LymphomaPaul A Hamlin, Vasile Musteata, Steven I Park, et al.
Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Acta Biomaterialia|September 6, 2017
Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticlesChristina L Parker, Qi Yang, Bing Yang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 2, 2017
Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigensQi Yang, Christina L Parker, Yukang Lin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 27, 2020
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagiaKristyn Y DiSogra, Thuy Tran, Justin R Arnall, et al.
Cancer|December 15, 2018
Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypesLaura L Hester, Steven I Park, William A Wood, et al.
Archives of Pathology & Laboratory Medicine|February 2, 2013
Diagnostic complexities of eosinophiliaNathan D Montgomery, Cherie H Dunphy, Micah Mooberry, et al.
ACS Nano|January 24, 2018
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin LymphomaKin Man Au, Ashutosh Tripathy, Carolina Pe-I Lin, et al.
The Lancet. Oncology|November 19, 2013
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation studyAnas Younes, Joseph M Connors, Steven I Park, et al.
Blood Advances|June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Cancer Research Communications|March 6, 2023
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell LymphomaPaul A Hamlin, Vasile Musteata, Steven I Park, et al.
Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.
Pageof 5